The agency has provisionally determined that Selarsdi will be interchangeable with Stelara following the exclusivity ... a ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara.

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

Otulfi ® is an ustekinumab biosimilar for the reference product Stelara ® (ustekinumab ... and a 130 mg/26 mL (5 mg/mL) single dose vial for IV infusion. Otulfi in a 45 mg/0.5 mL single ...

The report noted that J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense deal with a private label provider, which J&J ...

Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA ...

As a major component of the Connect 360 Autoimmune Program expansion, SmithRx will help employer clients and their employees adopt biosimilars, representing over 95% savings compared to Stelara ...

The FDA has also provisionally determined that SELARSDI will be interchangeable with Stelara upon the expiration ... 45 mg/0.5 mL in a single-dose vial for subcutaneous injection and130 mg/26 ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

It encompasses all indications approved for the STELARA® reference product ... solution in a single-dose vial. Plaque Psoriasis (PsO) in adults and pediatric patients 6 years of age and older ...